Related Experiment Video

Updated: Jun 13, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

An update on targeted therapy in metastatic renal cell carcinoma

Giuseppe Lombardi1, Fable Zustovich, Martin Donach

  • 1Oncologia Medica 1, Istituto Oncologico Veneto-IRCCS, Padova, Italy. lombardi.giuseppe.lg@gmail.com

Urologic Oncology
|May 12, 2010
PubMed

Insights

Targeted therapies have transformed renal cell carcinoma treatment, but optimal strategies remain unclear. This review analyzes current targeted agents and discusses sequential and combination approaches for metastatic disease.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Renal cell carcinoma (RCC) pathogenesis involves deregulated biological pathways.
  • Targeted therapies have significantly altered RCC treatment paradigms.
  • Optimal therapeutic strategies for RCC remain under investigation.

Purpose of the Study:

  • To review recent data on established targeted agents for RCC.
  • To assess novel targeted drugs in RCC treatment.
  • To discuss sequential and combination targeted therapy for metastatic RCC.

Main Methods:

  • Literature review of published reports on targeted agents.
  • Analysis of clinical data for sunitinib, bevacizumab, sorafenib, temsirolimus, everolimus, pazopanib, and axitinib.
  • Evaluation of sequential and combination therapy strategies.

Main Results:

  • Established targeted agents (sunitinib, bevacizumab, sorafenib, temsirolimus, everolimus) have demonstrated efficacy.
  • Novel agents (pazopanib, axitinib) show promise in RCC treatment.
  • Lack of cross-resistance suggests potential for sequential and combination therapies.

Conclusions:

  • Targeted therapies offer improved options for renal cell carcinoma.
  • Further research is needed to define optimal sequencing and combinations.
  • Personalized treatment approaches may enhance outcomes in metastatic RCC.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...